Drug Profile
MSI 239
Latest Information Update: 14 Aug 2007
Price :
$50
*
At a glance
- Originator Genaera Corporation
- Class Antibacterials; Peptide antibiotics; Peptides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ophthalmic infections
Most Recent Events
- 06 Jul 1998 Profile reviewed
- 06 Jul 1998 No-Development-Reported for Ophthalmic infections in USA (Unknown route)
- 24 Feb 1995 Preclinical development for Ophthalmic infections in USA (Unknown route)